What are the precautions for Rubicatin/Rubicatin?

In clinical studies of lubicatin/Lurbinectedin in the treatment of metastatic small cell lung cancer (SCLC), warnings and precautions such as bone marrow suppression, hepatotoxicity, tissue necrosis caused by extravasation, rhabdomyolysis, and embryo-fetal toxicity have emerged. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Myelosuppression: Rubicatin can cause bone marrow suppression. In clinical studies, a small number of patients developed neutropenia, sepsis, thrombocytopenia, anemia and other symptoms. Rubicatin should only be administered to patients with a baseline neutrophil count of at least 1,500 cells/mm3 and a platelet count of at least 100,000 cells/mm3. Monitor blood cell counts, including neutrophil count and platelet count, before each dose. G-CSF is recommended for any neutrophil count below 500 cells/mm3 or below the lower limit of normal.

2. Hepatotoxicity: Rubicatin can cause hepatotoxicity. In clinical studies, a small number of patients experienced grade 3 elevations in ALT and AST, and grade ≥ 3 elevations in aminase. Monitor liver function tests before initiating rubicatin and periodically during treatment as clinically indicated.

3. Extravasation leads to tissue necrosis: Extravasation of rubicatin can cause skin and soft tissue damage, including necrosis that requires debridement. Consider the use of a central venous catheter to reduce the risk of extravasation, especially in patients with limited venous access. Monitor patients for signs and symptoms of extravasation during rubicatin infusion. If extravasation occurs, stop the infusion immediately, remove the infusion catheter, and monitor for signs and symptoms of tissue necrosis. The time to onset of necrosis after extravasation may vary. Manage supportive care and consult physician as needed about signs and symptoms of extravasation. Follow-up infusions are given in sites unaffected by extravasation.

4. Rhabdomyolysis: There have been reports of rhabdomyolysis in patients treated with rubicatin. Monitor creatine phosphokinase (CPK) before initiating rubicatin and periodically during treatment as clinically indicated.

5. Embryo-Fetal Toxicity: Based on animal data and its mechanism of action, rubicatin taken by pregnant women can cause harm to the fetus. During organogenesis, intravenous administration of a single dose of lurbinectedin (approximately 0.2 times the clinical dose of 3.2 mg/m2) to pregnant animals resulted in 100% death of rat embryos. Inform pregnant women of potential risks to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Advise male patients with a female partner of reproductive potential to use an effective method of contraception during treatment and for 4 months after the last dose.